Navigation Links
Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
Date:1/12/2011

STEWARTVILLE, Minn., Jan. 12, 2011 /PRNewswire/ -- Rochester Medical Corporation (Nasdaq: ROCM) today announced it had reached an agreement with Fornix N.V. to purchase from Fornix its wholly owned subsidiary Laprolan B.V., a medical supplies distribution company located in Beuningen, The Netherlands.  Laprolan distributes wound care, ostomy care and urology products into the Dutch market and had unaudited revenues of approximately euro 8.0 million (approximately $10.5 million) in calendar 2010.

Under the agreement, Rochester Medical will pay approximately euro 10.35 million (approximately $13.73 million) in cash for the shares of Laprolan B.V.  The transaction is subject to approval by the shareowners of Fornix N.V., which will convene an extraordinary general meeting of shareholders for such purpose as soon as possible with the aim to complete the transaction soon thereafter.  The transaction is expected to close at the latest by May 31, 2011, but will have a retroactive effective date of January 1, 2011.  

Commenting on today's announcements, Rochester Medical CEO and President Anthony J. Conway said, "This acquisition when completed fits nicely with our ongoing plan to expand our direct branded presence in mainland Europe.  Laprolan has provided quality products and service to its customers in the Netherlands for 25 years, including Rochester Medical's products for the past 16 years.  Laprolan has distribution rights to market leading products in wound care, ostomy care and urology products in the Netherlands and its product lines and sales presence are a welcome addition to the Rochester Medical product offering and team."

Conway concluded, "I am extremely pleased with this opportunity for Rochester Medical, and we look forward to completing this acquisition and making it a successful part of our future."

Rochester Medical plans to discuss the acquisition of Laprolan further during its first quarter 2011 earnings conference call scheduled for January 25, 2011.

This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the expected completion of the acquisition and financial results of Laprolan.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current economic conditions, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications.  The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at http://www.rocm.com.  More information about Laprolan B.V. is available at www.laprolan.nl.  


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Fourth Quarter and Year-End Results
2. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
3. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
4. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
5. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
6. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
7. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. DST HealthCare Launches Medical Drug Management Service™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin ... global anti-obesity drugs market is expected to grow at ... period and CAGR of 38.7% in the second half of the ... of 32.8% from 2016 to 2027. The market is estimated at ... in 2027. ...
Breaking Medicine Technology:
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming ... set out for each of his children. “The Angel” is the creation of published ... in New York City, and impassioned writer. , When asked of her new book, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “I Forgive You”: a fine examination ... “I Forgive You” is the creation of published author, Stephen Miller, who, for over ten ... has gracefully given to him. Born in Trinidad and Tobago, he has been serving the ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story of ... Seymour, who lives in Lafayette, Indiana where she works in a daycare and looks ... writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Knowledge is God’s ... guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene ... novels, and poetry collections. , “I have been writing since high school and ...
Breaking Medicine News(10 mins):